Achievement of Clinical Remission in Life-Threatening Rosai-Dorfman Disease With Cladribine
2024
Successful Treatment of Life-Threatening Rosai-Dorfman Disease with Cladribine
Sample size: 1
publication
Evidence: low
Author Information
Author(s): Muacevic Alexander, Adler John R, Leonhardt Lex P, Yamagata Hiroshi, Harcha John, Calvo Alejandro
Primary Institution: Kettering Health, Kettering, USA
Hypothesis
Can cladribine effectively treat life-threatening Rosai-Dorfman disease?
Conclusion
Cladribine treatment led to complete clinical and radiographic remission in a patient with severe Rosai-Dorfman disease.
Supporting Evidence
- The patient achieved clinical remission after six cycles of cladribine.
- Cladribine is a purine nucleoside analogue used for various hematological conditions.
- Previous studies have shown variable success with cladribine in treating Rosai-Dorfman disease.
Takeaway
A woman with a rare disease got better after taking a medicine called cladribine, which helped her feel normal again.
Methodology
The patient was treated with six cycles of cladribine, with monitoring of symptoms and imaging.
Limitations
The study is based on a single case, limiting generalizability.
Participant Demographics
A 40-year-old healthy Hispanic female.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website